Latest studies
- RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Hong Kong - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerHong Kong - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
Metastatic Non Small Cell Lung CancerHong Kong - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Hong Kong - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerHong Kong - RecruitingPHASE2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
This study is testing a new medicine, ADX-038, for adults with certain kidney diseases caused by a problem with the body's immune system, called the complement system. We want to see if it's safe and helps people with conditions like IgA nephropathy (IgAN) or C3 glomerulopathy (C3G).
IgANC3GComplement-mediated Kidney DiseaseIgA Nephropathy (IgAN)Hong Kong - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerHong Kong - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaHong Kong - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaHong Kong - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Hong Kong - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung Cancer, HER2 MutationHong Kong - RecruitingPhase III
Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema
This study looks at a new medicine called navenibart for hereditary angioedema (HAE). It aims to see how safe it is and how well people tolerate it over a long time. Navenibart might help prevent HAE attacks, which can be severe and painful.
Hereditary angioedemaHong Kong - Active not recruitingPHASE1
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
This study is looking into a new medicine called DFV890 for adults with certain myeloid diseases, like specific types of MDS, CMML, and CCUS. It aims to find the right dose and see how safe and effective it is.
Myeloid DiseasesHong Kong - Active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
Metastatic Castration-resistant Prostate CancerHong Kong - Active not recruitingPHASE3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
This study looks at a new medicine called ravulizumab for people with kidney disease having heart surgery. It aims to see if the medicine can prevent serious kidney problems after the operation. It's for adults aged 18-90.
Chronic Kidney DiseaseCKDCardiac DiseaseCardiopulmonary BypassHong Kong - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesHong Kong - Active not recruitingPHASE3
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is looking into a new drug, garetosmab, for adults with Fibrodysplasia Ossificans Progressiva (FOP). We want to find out if it's safe, how well it works, and if it helps with FOP symptoms. It's a Phase 3 trial, meaning it's in the later stages of testing.
Fibrodysplasia Ossificans ProgressivaHong Kong - RecruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaHong Kong - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
Breast CancerHong Kong - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisHong Kong - Enrolling by invitationPHASE2, PHASE3
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
This study looks at the long-term safety and effects of a medicine called sibeprenlimab for people with a kidney condition called IgA Nephropathy. It's for those who have already been part of earlier studies with this medicine.
Immunoglobulin A NephropathyHong Kong - Active not recruitingPHASE4
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
This study is looking at a new treatment called guselkumab for people with psoriatic arthritis that affects the spine and pelvis. It aims to see how well it reduces pain and inflammation in these areas. Participants will receive either the study drug or a dummy treatment.
Arthritis, PsoriaticHong Kong - Active not recruitingPHASE2
Study of Novel Treatment Combinations in Patients With Lung Cancer
This study looks at new drug combinations to treat lung cancer. It has three parts: for cancer that has spread, cancer that has grown despite previous treatment, and earlier-stage cancer that can be removed by surgery.
Lung CancerAdvanced or Metastatic Non-Small-Cell Lung CancerResectable Non-Small-Cell Lung CancerHong Kong - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
This study is testing a new medicine called sefaxersen for people with a kidney disease called IgA nephropathy. We want to see if it's safe and helps slow down kidney damage, especially for those at higher risk.
Primary IgA NephropathyHong Kong - Active not recruitingPHASE3
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
This study is testing a new medicine called pelabresib alongside an existing treatment (ruxolitinib) for adults with myelofibrosis who haven't tried similar drugs before. It aims to see if this combination works better than ruxolitinib alone to help manage symptoms and spleen size.
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisHong Kong - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerHong Kong - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesHong Kong - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
Gastric CancerGastroesophageal Junction CancerHong Kong - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCHong Kong - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisHong Kong - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
Non-small Cell Lung CancerHong Kong - Active not recruitingPHASE3
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.
ArteriosclerosisHypercholesterolaemiaHong Kong - Active not recruitingPHASE3
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, selpercatinib, to see if it can stop lung cancer from coming back after surgery or radiation. It's for people with a specific type of non-small cell lung cancer.
Carcinoma, Non-Small-Cell LungHong Kong - Active not recruitingPHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
This study compares a new medicine, crovalimab, to an existing one, eculizumab, for people with a rare blood condition called PNH. It's looking at how safe and effective crovalimab is in patients already receiving similar treatments.
Paroxysmal Nocturnal HemoglobinuriaHong Kong - Active not recruitingPHASE3
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
This study compares a new drug, TAK-788, with standard chemotherapy for advanced lung cancer (NSCLC) where the cancer has a specific genetic change (EGFR exon 20 insertion mutation). It's for people who haven't had prior treatment for their advanced cancer.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Hong Kong - Active not recruitingPHASE2
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
This study is testing a new medicine, Alpelisib, for children and adults with a condition called PIK3CA-related overgrowth spectrum (PROS). Researchers want to see if it's safe and effective in helping manage the overgrowth caused by this condition.
PIK3CA-related Overgrowth Spectrum (PROS)Hong Kong - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerHong Kong - Active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
This study looks at a new drug, selpercatinib, for people with a type of lung cancer that has spread. It compares this new drug to standard treatments to see if it's safe and works well for their specific cancer type.
Non-Small Cell Lung CancerHong Kong - RecruitingPHASE3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
This study is testing a new drug, Elacestrant, against standard hormone treatments for early breast cancer. It's for men and women whose cancer is ER-positive and HER2-negative, and has a high chance of coming back. The aim is to see if Elacestrant works better.
Breast CancerHong Kong - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
Hepatocellular CarcinomaHong Kong - Active not recruitingPHASE3
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study compares a new drug, DS-1062a, with a standard chemotherapy, docetaxel, for advanced lung cancer. It's for people whose cancer has grown after previous treatments. We want to see if DS-1062a is safer and works better.
Non-small Cell Lung CancerHong Kong - RecruitingPHASE1, PHASE2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
This study is testing a new drug, ORIC-114, for people with advanced cancers that have specific changes in their EGFR or HER2 genes. It's looking at how safe the drug is, the best dose, and if it can shrink tumours, either alone or with chemotherapy.
Solid TumorsHong Kong - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
Breast NeoplasmsHong Kong - RecruitingPHASE3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in people who are newly diagnosed. It's comparing a new drug, bleximenib, with existing treatments (Venetoclax and Azacitidine) and a dummy drug (placebo) to see how well they work.
Leukemia, Myeloid, AcuteHong Kong - RecruitingPHASE3
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial
The LOLIPOP trial is studying a common pain medication called lidocaine, given into a vein during and after breast cancer surgery. We want to see if it helps reduce long-term pain and is safe for patients.
Breast CancerBreast Cancer FemaleBreast Conserving SurgeryMastectomyHong Kong - RecruitingPHASE1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
This study looks at a new treatment called AZD5492 for lupus, myositis, and rheumatoid arthritis. It checks how safe it is, how well the body handles it, and how it works in adults.
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesRheumatoid ArthritisHong Kong - Active not recruitingPHASE2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
This study is testing new medicines, daplusiran/tomligisiran (DAP/TOM) and bepirovirsen, for people with long-term Hepatitis B. It aims to find the best dose of DAP/TOM to use with bepirovirsen to improve treatment.
Chronic Hepatitis B Virus InfectionHepatitis BHong Kong - Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
Hepatocellular CarcinomaBiliary Tract CancerHong Kong - Active not recruitingPHASE3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
This study looks at a new combination of medicines, savolitinib and osimertinib, for people with a type of lung cancer that has gotten worse after treatment with osimertinib. It compares this new combination to standard chemotherapy to see if it works better and is safe.
CarcinomaNon-Small-Cell LungHong Kong - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
Non-small Cell Lung CancerHong Kong